Meeting
2013 ASCO Annual Meeting
Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC).
Authors
Julien Taïeb
Georges Pompidou European Hospital, Paris, France
Julien Taïeb , Josep Tabernero , Enrico Mini , Fabien Subtil , Gunnar Folprecht , Jean-Luc Van Laethem , Joseph Thaler , John A. Bridgewater , Evaristo Sanches , Lone Petersen , Laurence Collette , Eric Van Cutsem , Karine Le Malicot , Philippe Rougier , Ramon Salazar , Laurent Bedenne , Jean Francois Emile , Pierre Laurent-Puig , Come Lepage
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00265811
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3525^)
DOI
10.1200/jco.2013.31.15_suppl.3525
Abstract #
3525^
Poster Bd #
17
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Final results of the ACTS-CC 02 trial: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer.
First Author: Naohiro Tomita
Poster
2013 Gastrointestinal Cancers Symposium
Effectiveness of capecitabine plus oxaliplatin for advanced colon cancer: A public hospital experience.
First Author: Carrie Luu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
First Author: Iwona A. Lugowska